Citadel Advisors
IMNM icon

Citadel Advisors’s Immunome IMNM Stock Holding History

Citadel Advisors’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$516K Sell
23,600
-45,500
-66% -$1.01M ﹤0.01% 9224
2025
Q4 		$1.48M Buy
69,100
+49,500
+253% +$869K ﹤0.01% 6535
2025
Q3 		$230K Hold
19,600
– – ﹤0.01% 10947
2025
Q2 		$182K Buy
19,600
+10,800
+123% +$88.5K ﹤0.01% 10763
2025
Q1 		$59.2K Sell
8,800
-2,400
-21% -$23K ﹤0.01% 12127
2024
Q4 		$119K Buy
11,200
+2,800
+33% +$33.8K ﹤0.01% 11207
2024
Q3 		$123K Sell
8,400
-14,700
-64% -$209K ﹤0.01% 10840
2024
Q2 		$280K Buy
23,100
+10,100
+78% +$158K ﹤0.01% 9278
2024
Q1 		$321K Sell
13,000
-1,200
-8% -$24.4K ﹤0.01% 9308
2023
Q4 		$152K Sell
14,200
-4,800
-25% -$39.9K ﹤0.01% 10359
2023
Q3 		$159K Buy
19,000
+10,500
+124% +$77.1K ﹤0.01% 10270
2023
Q2 		$67.2K Buy
8,500
+2,400
+39% +$13.1K ﹤0.01% 11449
2023
Q1 		$30.4K Buy
+6,100
New +$29.8K ﹤0.01% 12725
2021
Q4 		– Sell
-18,700
Closed -$455K – 14248
2021
Q3 		$455K Buy
+18,700
New +$326K ﹤0.01% 10106

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Citadel Advisors's IMNM Position: Q1 2026 in Review

Citadel Advisors reduced its Immunome (IMNM) stake by 95% in Q1 2026, selling an estimated $37M and leaving 80,197 shares worth $1.75M. The position accounts for ﹤0.01% of the portfolio, ranked #6364.

Citadel Advisors first reported a position in IMNM in Q3 2021 and has held it in 13 quarters since. The position peaked at $37.4M in Q4 2025. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Citadel Advisors held 80,197 shares of Immunome worth $1.75M as of Q1 2026.
  • Citadel Advisors sold 1,660,508 Immunome shares in Q1 2026, an estimated $37M.
  • Immunome made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6364 holding.
  • Citadel Advisors first reported a position in Immunome in Q3 2021 and has held it in 13 quarters since.
  • Citadel Advisors's Immunome position peaked at $37.4M in Q4 2025.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.